A portrait photo

David Alexander Lindsay, Ph.D.

Director, Vaccine Clinical Materials Program


Dr. David Lindsay is the directorate head of the Vaccine Clinical Materials Program. He is responsible for the scientific, technical and administrative oversight and operation of a good manufacturing practices (GMP) vaccine pilot plant.

At present, the pilot plant is engaged in all aspects of product development relating to novel, structure-based vaccines, nanoparticles and peptide conjugates for HIV and Influenza, as well as a variety of different mAbs directed at different HIV epitopes, and unique Ebola virus and Malaria targets.  

David holds a B.S. degree in Chemical Engineering from Lafayette College (Easton, PA) and a Ph.D. from Johns Hopkins University (Baltimore, MD). With research interests straddling the fields of Virology and Bio/Chemical Engineering, David is a passionate leader that believes in advancing science-based, collaborative partnership-based solutions to public health challenges faced by patients nationally and globally. He has over 24 years of industry experience, including cell culture process development to tech transfer to clinical and commercial manufacture of biologics/recombinant vaccines. Prior to joining the FNL in March 2015, David worked at MedImmune LLC-Astra Zeneca in both Gaithersburg and Frederick locations (2002-2014), Schering-Plough Research Institute in Union, New Jersey (1995-2002), and the University of Maryland at College Park’s bioprocess scale-up facility (1994-1995).